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Abstract
Background
HIV infection results in damage to the gastrointestinal (GI) tract, microbial translocation and
immune activation. These are not completely normalized with combined antiretroviral ther-
apy (cART). Moreover, increate morbidity and mortality of cART-treated HIV-infected indi-
viduals is associated with inflammation.
Methods
In order to enhance GI tract immunity, we recruited and treated 20 HIV-infected humans
with cART supplemented with probiotics and followed inflammation and immunological
parameters (clinical trial number NCT02164344). 11 HIV seronegative subjects were
included as control group. The enumeration of CD4+, CD8+, CD38+ and HLA-DR+ lympho-
cytes were evaluated on peripheral blood; HIV-RNA levels, sCD14, d-dimer, C-reactive pro-
tein (CRP) high sensitivity C-reactive protein (hsCRP), IL-6 and Lipopolysaccharide Binding
Protein (LBP) were assayed on plasma.
Results
We observe that cART does not normalize the levels of immune activation in HIV positive
patients anyway inflammation and markers of microbial translocation were significantly
reduced with probiotic supplementation. Patients show a clear and statistically significant
reduction in the levels of immune activation on CD4 T-lymphocytes, for both markers CD38
and HLA-DR and their simultaneous expression, LBP and hsCRP plasma levels after probi-
otic diet supplementation settling to values comparable to controls.
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Conclusions
Supplementing cART with probiotics in HIV-infected individuals may improve GI tract immu-
nity and there by mitigate inflammatory sequelae, ultimately improving prognosis.
Trial Registration
ClinicalTrials.gov NCT02164344
Introduction
The life expectancy of HIV infected patients has dramatically changed after the introduction of
combined antiretroviral therapy (cART). However cART-treated patients still have increased
mortality and morbidity compared to age-matched seronegative individuals which involves
cardiovascular disease, neurocognitive disorders, liver and kidney disease and some cancers
[1]. This increased mortality and morbidity has been associated to immune activation that per-
sists also in patients under cART even with undetectable levels of HIV-RNA in blood [2–4].
Indeed HIV-infected patients show higher levels of activated T cells, inflammatory monocytes
and proinflammatory cytokines than seronegative individuals, irrespective of cART [5–6]. Sev-
eral putative causes of this residual inflammation have been proposed and include ongoing
HIV replication at low levels, the presence of coinfections, and microbial translocation. For
these reasons the consequent residual inflammation in cART treated individuals will require
novel therapeutic interventions aimed at alleviated each putative cause [7–19]. Here we aim to
reduce immune activation related to microbial translocation with supplementation of cART
with a probiotic mixture. Indeed, the early stage of HIV infection is associated with dysbiosis of
the GI tract microbiome with reduced levels of bifidobacteria and lactobacillus species with
increased levels of potentially pathogenic proteobacteria species. We conducted a longitudinal
study in HIV infected patients in cART and with persistent undetectable plasma levels of
HIV-RNA to investigate the potential benefits of 48 weeks of probiotics supplementation on
immune function and on immune activation status.
Material and Methods
Study design, recruitment and study eligibility criteria
The protocol for this trial and supporting TREND checklist are available as supporting infor-
mation; see S1 TREND Checklist, S1 Protocol (Protocol in Italian), and S2 Protocol (Protocol
in English). This is a longitudinal pilot study (Fig 1). This study, named “Probio-HIV”, is regis-
tered on the ClinicalTrials.gov registry with identifier number NCT02164344. Study partici-
pants included a total of 20 HIV-infected patients and 11 healthy donors enrolled from
January 2013 to September 2013 from the Department of Public Health and Infectious Diseases
of the University of Rome“Sapienza”.
The inclusion criteria allowed to enroll HIV-positive patients who have signed the informed
consent and aged between 18 and 80 years. Moreover, in order to avoid the influence of previ-
ous cART exposure, active viral replication and switches of treatment, the eligibility criteria
allowed to enrol patient under cART with persistent undetectable levels of HIV-RNA (detec-
tion limit of viremia in routinely clinical monitoring of the patients: 37 copy/mL measured
with Versant kPCR) and without history of drugs failure. Other inclusion criteria included: i)
no change in antiretroviral therapy since the beginning of the cARV treatment, ii) no history of
AIDS-defining conditions from the diagnosis of HIV to the enrolment iii) no current diagnosis
of acute infection.
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At baseline (T0) the evaluation of immune activation of all subjects was performed. HIV-1
infected patients were then asked to take daily dietary supplement with probiotics (1 g packet
containing Streptococcus salivarius ssp. Termophilus [at least 204 billion Colony Forming
Unit—CFU], Bifidobacteria–represented by B. breve, B. infantis and B. longum [at least 93 bil-
lion CFU], Lactobacillus acidophilus [at least 2 billion CFU], Lactobacillus plantarum [at least
220 million CFU], Lactobacillus casei [220 million CFU], Lactobacillus delbrueckii ssp. Bulgari-
cus [at least 300 million CFU] and Streptococcus faecium [at least 30 million CFU]) for 48
weeks, twice a day. A second evaluation of their immune activation was performed 48 weeks
after the baseline analysis (T1). The healthy subjects did not consume probiotics, and were
used as controls of treatment group to compare immune activation levels.
A self-administered questionnaire was fulfilled by participants at the end of probiotics’
intake to investigate their effects on bowel activity.
Ethics Statement
The study was approved by the institutional review board (Department of Public Health and
Infectious Diseases, University of Rome ‘‘Sapienza” and Ethics Committee Azienda Policlinico
Umberto I of Rome). All study participants gave informed written informed consent and the
research was conducted in accordance with the Helsinki Declaration of 1975 and revised in
Fig 1. The CONSORT flow diagram of the clinical trial. Experimental design of the study.
doi:10.1371/journal.pone.0137200.g001
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2000. The approval of the independent Ethics Committee is the only form of registration
required by Italian law; for this reason, the registration in an international registry was made
after patient recruitment. Moreover the authors confirm that all ongoing and related trials for
this intervention are registered.
CD4+, CD8+, CD38+ and HLA-DR+ lymphocyte counts. Peripheral blood samples
were collected in tubes containing ethylenediaminetetraacetic acid and Lyse/Wash Procedure
was applied; lymphocytes T cells enumeration and activation were evaluated by the following
anti-human monoclonal antibodies: CD3 VioBlue, CD 4 APC-Vio770, CD8 FITC, CD38 APC
and HLA-DRPE (MiltenyiBiotec). 5-color flow cytometric analysis was performed with the
MiltenyiBiotec flow citometer-MACSQuantAnalyzer (8 fluoresces, 3 lasers). Gating analysis
was developed with MACSQuantify software 2.5 (MiltenyiBiotec) with the same gating strategy
applied to all samples. We tested specificity for the expression of CD38 and HLA-DR markers,
by using Fluorescence Minus One method (FMO): each cell population was stained with all the
fluorescence antibodies, except one, at a time, in order to verify whether in the absence of one
antibody, the labelled cells were negative for the removed one; this method allows the subset to
be gated and the background level for the subset to be determined.
Plasma markers of microbial translocation and immune activation. EDTA plasma was
used to perform Enzyme linked Immunosorbent Assays. Commercially available ELISAs were
used to quantify plasma levels of sCD14 (R&D Systems, Minneapolis, MN, detection limit 125
pg/mL), D-dimer (Wuhan Hubei Province, China, detection limit 3.9 ng/mL), C-reactive pro-
tein (R&D Systems, Minneapolis, MN, detection limit 23 pg/mL), hsCRP (BioVendor R&D,
Torino, detection limit 0.02 μg/mL), IL-6 (R&D Systems, Minneapolis, MN, detection limit 1
pg/mL) and LBP (Enzo Life Sciences, Florence, detection limit 25 ng/mL). All were performed
according to the manufacturer’s protocols and absorbances were read at 450 nm with an auto-
mated Microplate Reader (BIO-RAD).
HIV-RNA levels
HIV-RNA levels were measured in plasma prepared from blood obtained in EDTA-containing
tubes and stored at -70°C. A quantitative reverse polymerase chain reaction was measured with
Versant kPCR (Siemens Healthcare Diagnostics). The limit of detection was 1 copy/mL.
Questionnaires. A self-administered questionnaire was fulfilled by participants at the end
of the study to investigate probiotics’ actual intake and their effects on bowel activity.
The questionnaire included personal data such as age, level of education and work; it was
administered to assess the duration and the intake period of probiotics, the regularity with
which such an assumption had been made and benefits/inconvenience perceived; since the
purchase was charged to the patient, we asked if the cost has been excessive. We also inquired
if in the past they had already made use of lactic acid bacteria.
Statistical analysis. Statistical analysis were performed with SigmaStat software (version
2.03). Prior to the statistical analyses, normal distribution and homogeneity of the variances
were tested. Values are given as mean and standard deviation (SD). For comparison of the
immune activation between the two different times of analysis, we used Paired t-test or Wil-
coxon signed-rank test when the data showed a non-Gaussian distribution; to compare the
data with the control group a simple t-test (MannWhitney U-test for skewed distributed vari-
ables) was performed. and correlations were determined by nonparametric Spearman's rank
test. P values<0.05 were considered statistically significant.
All graphs were generated by using GraphPad Prism (version 5.00) and SigmaPlot software
(version 8.0).
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Results
Patient population
20 HIV-1 infected individuals, 3 women and 17 men, were recruited and underwent a blood
collection. The median age was 54 years (range 27–72). All subjects were on cART from at least
3 years (median 12,5 years; range 3–20) and had a median of CD4+ T cell count of 542 cells/μl
(range 285–1402) and HIV RNA<50 copies/mL at the moment of enrolment.11 HIV seroneg-
ative subjects were included as control group, age ranging from 28 to 73 years with a median
age of 43 (7 women and 4 men).
Table 1 shows the basic demographic, immunological and virological characteristics of the
20 HIV-infected patients who were included in the study. Tables 2 and 3 show respectively the
changes in value of cellular activation levels and of plasma cytokines concentrations from T0 to
Table 1. Demographic, immunological and virological characteristics of the 20 HIV-infected patients and 11 controls included in the study.
Pts&Ctrs Age
(Yrs)
Sex TherapyCurrent CD4+(Cell/
μL) Nadir
CD4+(Cell/
μL) T0
CD4+%
T0
CD4+(Cell/
μL) T1
CD4+%
T1
HIV-RNA
(copies/mL) T0
HIV-RNA
(copies/mL) T1
P1 49 M treated 300 550 19,07 727 25,67 36 37
P2 47 M treated 63 426 12,88 595 20,46 22 1
P3 68 M treated 300 579 22,52 691 24,57 1 1
P4 59 F treated 50 767 39,12 714 36,91 1 1
P5 67 M treated 16 329 7,47 429 14,37 1 1
P6 55 M treated 70 608 21,38 455 17,51 1 1
P7 27 M treated 50 394 14,34 389 17,85 1 1
P8 57 F treated 50 527 23,25 348 19 50 29
P9 44 M treated 300 1402 33,88 1244 36,1 1 1
P10 49 M treated 20 467 23,01 446 25,91 1 9
P11 46 M treated 29 629 33,78 672 34,21 8 30
P12 64 M treated 300 897 36,86 862 34,81 1 1
P13 57 M treated 350 597 24,07 686 26,03 13 1
P14 72 M treated 50 285 16,4 180 18,01 9 1
P15 51 F treated 180 833 21,84 897 27,38 1 1
P16 53 M treated 69 402 21,75 454 28,46 1 22
P17 72 M treated 280 533 43,16 581 39,15 1 1
P18 44 M treated 150 640 37,89 503 36,82 1 1
P19 40 M treated 400 513 43,63 825 44,77 16 1
P20 57 M treated 200 530 32,69 638 33,92 1 1
C1 32 M untreated - - 57,87 - - 0 0
C2 29 F untreated - - 48,21 - - 0 0
C3 51 F untreated - - 61,59 - - 0 0
C4 43 M untreated - - 38,49 - - 0 0
C5 73 F untreated - - 40,96 - - 0 0
C6 28 F untreated - - 50,24 - - 0 0
C7 44 F untreated - - 55,45 - - 0 0
C8 50 F untreated - - 50,74 - - 0 0
C9 36 F untreated - - 65,74 - - 0 0
C10 49 M untreated - - 72,17 - - 0 0
C11 28 M untreated - - 68,54 - - 0 0
doi:10.1371/journal.pone.0137200.t001
Probiotics and Inflammation in HIV Positive Patients
PLOS ONE | DOI:10.1371/journal.pone.0137200 September 16, 2015 5 / 15
T1 in HIV population. Moreover Table 3 compares also the T1 values registered in HIV+
patients with those observed in healthy controls. There were no adverse events in any of sub-
jects enrolled; furthermore none patients required modification to their treatment regimen and
none reported clinical progression.
cART does not normalize the levels of immune activation. As expected, the percentage
levels of CD4+ T cells in the sample are significantly lower compared to healthy controls,
respectively 26.45±10.46 (media±SD) and 55.45±10.95 (p<0.001). The levels of immune acti-
vation instead were higher in HIV+ patients than in healthy controls (CD4+/CD38-/DR+ in
HIV+ patients and healthy controls, were respectively 11.18±8.58 vs 4.05±2.46, p<0.001).
The double activated subsets, both CD4+/CD38+/HLA-DR+ and CD8+/CD38+/HLA-DR+
show in HIV+ levels strongly higher, respectively 2.57±1.42 and 5.23±4.45, compared with
those in healthy donors (1.28±1.26 and 2.84±5.17, p = 0.002).
Impact of probiotics on CD4 T-cells. A weak increase in CD4 percentages and absolute
numbers among HIV-1 infected patients between T0 and T1 was observed (respectively 26.45
±10.46 and 28.1±8.62, p = 0.065) with median recovery of 65 cell/μL.
Table 2. Patients and Controls’ CD4 and CD8 immune activation markers’ mean values, standard deviations and T-test p-values.
MEAN
T0
STD.
DEV. T0
MEAN
T1
STD.
DEV. T1
PAIRED
T-TEST
p-values
MEAN
CONTROLS
STD. DEV.
CONTROLS
T-TEST p-values
controls/HIV+ T0
T-TEST p-values
controls/HIV+ T1
CD4+CD38
+HLA-DR-%
17,24 11,84 11,23 8,49 0,004 20,93 12,31 0,42 0,015
CD4
+CD38-HLA-DR+
%
11,18 8,58 8,2 6,65 0,001 4,05 2,45 <0,001 0,008
CD4+CD38
+HLA-DR+%
2,57 1,42 1,24 0,68 <0,001 1,28 1,26 0,002 0,47
CD8+CD38
+HLA-DR-%
4,98 3,63 3,29 4,54 0,237 3,31 1,84 0,166 0,143
CD8
+CD38-HLA-DR+
%
14,17 11,16 13,23 9,41 0,608 7,26 4,57 0,06 0,026
CD8+CD38
+HLA-DR+%
5,23 4,45 2,78 2,28 0,015 2,84 5,17 0,002 0,208
doi:10.1371/journal.pone.0137200.t002
Table 3. Plasmamarkers’ mean values, standard deviation and t-test p-values at both analysis time in patients and their comparison with
controls.
MEAN
T0
STD.
DEV. T0
MEAN
T1
STD.
DEV. T1
PAIRED
T-TEST
p-values
MEAN
CONTROLS
STD. DEV.
CONTROLS
T-TEST p-values
controls/HIV+ T0
T-TEST p-values
controls/HIV+ T1
sCD14
ng/mL
1941,59 492,29 1925,74 507,74 0,812 1296,92 309,29 <0,001 <0,001
d-dimer
ng/mL
93,8 148,98 79,44 125,91 0,182 7,58 8,54 0,008 0,024
CRP ng/
mL
2677,51 2468,92 1723,74 1246,68 0,095 1685,68 1630,40 0,243 0,942
hsCRP
mg/L
3,36 2,95 1,62 1,42 0,006 1,08 1,33 0,022 0,186
IL-6 pg/
mL
3,89 5,14 2,22 3,80 0,027 1,02 0,63 0,291 0,885
LBP μg/
mL
26,94 6,16 25,4 4,48 0,266 22,52 3,07 0,035 0,068
doi:10.1371/journal.pone.0137200.t003
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Changes in markers of immune activation during the 48 weeks of
probiotic diet supplementation
In this analysis, the levels of immune activation were compared between cART-treated HIV-
infected individuals before probiotics (T0), and after probiotic intake (T1). Comparing T1 to
T0, the percentage of CD4+CD38+HLA-DR+ T cells was significantly lower (respectively 1.24
±0.68 and 2.57±1.42, p<0.001). The same trend was observed in CD8+CD38+HLA-DR+ T
cells, patients showed a percentage of 5.23±4.45 before and a percentage of 2.78±2.28 after lac-
tic acid bacteria intake (p = 0.015).
Moreover, despite a significantly higher percentage of CD4+CD38+HLA-DR+ and CD8+
CD38+HLA-DR+ T cells observed at T0 in HIV-1 infected subjects compared to HIV seroneg-
ative donors (p = 0.002), the expression of activation markers on CD4 and CD8 surface at T1
resulted comparable to healthy donors (Fig 2).
No correlation was found between patients’ CD4 nadir and the CD4 recovery (ΔCD4), both
T0 and T1. A positive correlation was found instead between the ΔCD4 at T0 and the ΔCD4 at
T1 (r = 0.603, p = 0.004).
sCD14, D-dimer and LBP in HIV-infected patients treated with cART at T0 were signifi-
cantly higher than the levels found in healthy donors (91% of the controls had undetectable
level of D-dimer). These differences persist at T1 with the exception of LBP that normalizes
itself, showing values similar to controls (p = 0.068) (Fig 3).
Fig 2. Immune activation on T-lymphocytes. Longitudinal assessment of activation markers(CD38+HLA-DR+) on CD4+ cells (A) and on CD8+cells (B)
before (T0) and after (T1) probiotic diet supplementation. Control group was added for comparison. Horizontal bars in the scatter plot represent mean value
with SD. P values <0.05 were considered statistically significant.
doi:10.1371/journal.pone.0137200.g002
Fig 3. Plasma levels of sCD14, d-dimer and LBP. Scatter plots of sCD14 (A), d-dimer (B) and Lipopolysaccharide Binding Protein (LBP)(C) in patients
before (T0) and after probiotics’ intake (T1) compared with controls. Horizontal bars in the scatter plot represent mean value with SD. P values <0.05 were
considered statistically significant.
doi:10.1371/journal.pone.0137200.g003
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IL-6 and CRP in HIV-1+ patients are similar to that found in control group at both observa-
tion times. On the contrary, the mean of hsCRP at T0 was 3.36±2.95mg/L and 1.625±1.42 mg/
L at T1 (p = 0.006), becoming comparable to healthy donors (1.08±1.33, p = 0.186)(Fig 4).
By the Spearman’s rank sum test, the hsCRP level at T0 correlates positively with sCD14
(Correlation coefficient (CC):0.631, p = 0.002), IL-6 (CC:0.661, p = 0.001) and LBP (CC: 0.487,
p = 0.029) and negatively with the D-dimer (CC:-0.553, p = 0.011). sCD14 and IL-6 are posi-
tively associated with Correlation coefficient 0.621 and p = 0.003.
These correlations disappear at the second time of analysis. On the other hand we observed
a weakly significant correlation at T0 between sCD14 and D-dimer (p = 0.069) that persisted to
T1 (CC: -0.484, p = 0.030).
Finally the patients declared in the questionnaire that they did not regularly consume the
probiotics prior to enrollment in the study.
Aging and immune activation
The sample was divided according to the median age, less or greater than 55 years old; the
two groups were compared for levels of immune activation shown. There is differential activa-
tion of CD4 cells at T0: patients younger than 55 years show preferential activation of CD4+
CD38+ % T-cells subpopulation (22.85±13.37 vs 11.62±6.87 in the older group, p = 0.030)
Fig 4. HsCRP plasma levels.High-sensitivity C-reactive protein (hsCRP) distribution in patients before (T0), and after probiotics’ assumption (T1) compared
with controls Horizontal bars in the scatter plot represent mean value with SD. P values <0.05 were considered statistically significant.
doi:10.1371/journal.pone.0137200.g004
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whereas there is a more pronounced activation of CD4+HLA-DR+ T-cells subpopulation in
patients who are 55 years or older (15.19±10.53 versus 7.16±2.97 in the younger group,
p = 0.032). Nevertheless, after taking probiotics, both groups show a statistically significant
trend of reduction in the expression and co-expression of activation markers CD38 and
HLA-DR on CD4 + T-lymphocytes, regardless of age (Fig 5).
However, the levels of CD4+CD38+HLA-DR+% T-cells shown by the older group at T1,
are significantly higher than the other group (respectively 1.56±0.79 and 0.91±0.34, p = 0.027),
thus showing a lower recovery. In this group CD4+CD38+HLA-DR+% T-cells fraction at T0 is
also directly correlated to sCD14 levels (CC: 0.661, p = 0.033) and inversely related to d-dimer
(CC: -0.644, p = 0.038). Moreover we observed a reduction of the levels of activated CD8 in
both group, under and above 55 years, without statistically significant differences (Table 4).
In the group with less than 55 years, Interleukin 6 post-probiotic treatment falls to lower
levels (5.97±6.48 pg/mL before and 1.81±2.00 pg/mL after, p = 0.037) and its levels are always
Fig 5. Levels of immune activation according to the age on CD4+ T-cells. Extent of expression and co-expression of activation markers CD38 and
HLA-DR on CD4+ T-lymphocytes before (T0) and after probiotics’ intake (T1) in patients with less (A) and more (B) than 55 years. Horizontal bars in the
scatter plot represent mean value with SD. P values <0.05 were considered statistically significant.
doi:10.1371/journal.pone.0137200.g005
Table 4. Immune activationmarkers’ mean values, standard deviations and paired T-test p-values according to the age of patients.
MEAN
T0 pts>
55 yrs
STD. DEV.
T0
pts > 55
yrs
MEAN
T1 pts>
55 yrs
STD.DEV.
T1
pts > 55
yrs
PAIRED T-TEST
p-valuespts > 55yrs
MEAN
T0 pts<
55 yrs
STD. DEV.
T0
pts < 55
yrs
MEAN
T1 pts<
55 yrs
STD.DEV.
T1
pts < 55
yrs
PAIRED
T-TEST
p-values
pts < 55yrs
CD4+CD38
+HLA-DR-%
11,63 6,87 8,56 5,73 0,029 22,85 13, 3 13,89 10,17 0,022
CD4
+CD38-HLA-DR
+%
15,19 10,53 10,83 8,46 0,01 7,17 2,98 5,57 2,50 0,012
CD4+CD38
+HLA-DR+%
2,62 1,15 1,56 0,79 0,018 2,51 1,7 0,91 0,33 0,021
CD8+CD38
+HLA-DR-%
5,60 4,04 3,07 5,07 0,264 4,35 3,25 3,51 4,21 0,657
CD8
+CD38-HLA-DR
+%
17,3 13,9 17,83 11,27 0,857 11,04 6,92 8,62 3,58 0,301
CD8+CD38
+HLA-DR+%
6,18 5,47 3,69 2,82 0,187 4,28 3,13 1,87 1,08 0,074
doi:10.1371/journal.pone.0137200.t004
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positively correlated to sCD14 plasma values (CC: 0.732, p = 0.013 at T0; CC: 0.696, p = 0.022
at T1). In the older group is instead hsCRP to achieve a significant reduction, reaching a level
of 1.26±1.37 mg/L at T1 (2.73±2.69 mg/L at T0, p = 0.014) with a persistent positive correlation
with sCD14 (CC: 0.624, p = 0.048 at T0; CC: 0.644, p = 0.038 at T1).
Nadir and immune activation. The enrolled subjects were divided according to the
CD4-nadir (less than or greater than 250 cells/μl).
There are no appreciable differences in the levels of immune activation between the two
groups at T0 and T1, for both CD4 and CD8 T-cells.
The subjects with CD4 T-cells count greater than 250 (7 pts) have a significant decrease
only of the activation markers CD38, on both CD4 (12.11±6.18 at T0 and 7.62±3.31 at T1,
p = 0.028) and CD8 (3.86±1.82 at T0 and 1.72±1.52 at T1, p = 0.032).
Those who had a CD4 count less than 250 cells/μL (13 patients) instead show a clear reduc-
tion in the levels of immune activation on CD4 T-lymphocytes, for both markers CD38 (20.00
±13.39 at T0 and 13.17±9.85 at T1, p = 0.025) and HLA-DR (10.94±5.33 at T0 and 7.72±3.35
at T1, p = 0.008). The same trend was observed in the double activated CD4 subpopulation
(2.66±1.10 at T0 and 1.39±0.74 at T1, p = 0.002) (Fig 6). No appreciable reduction was found
for the activation of CD8+ T cells.
IL-6 levels at T0 were inversely correlated to CD4-Nadir (CC: -0.524, p = 0.015) and CD4%
(CC: -0.537, p = 0.015), and positively correlated with the frequencies of activated, CD4+CD38+
T-cells (CC: 0.492, p = 0.027) (Fig 7). Although we observed that IL-6 levels were decreased after
probiotic administration (p = 0.027), the negative correlation between CD4 and the levels of IL-6
only hold if pre-treatment (T0) data are included, presumably because this “pathology” is
improved with the probiotics.
Years of infection and immune activation. Dividing the sample according to the years
elapsed from infection (less than or greater than 10 years), we investigated the effective reduc-
tion of immune activation that occurs in the two groups and the difference between them.
Fig 6. Effects of probiotics on T-cells activation in patients with CD4 count less than 250 cells/μl. Longitudinal assessment of CD38 and HLA-DR
markers and their simultaneous expression on CD4 T cells in peripheral blood. in patients with a CD4 count less than 250 cells/μl at HIV infection diagnosis.
P values <0.05 were considered statistically significant.
doi:10.1371/journal.pone.0137200.g006
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Both groups start at comparable levels of CD4 T-cells immune activation (respectively 2.68
±1.68 in the group infected by more time and 2.40±0.99 in the other group) and show similar
value at T1 (respectively 1.37±0.8 and 1.03±0.42). However, the reduction in the levels of CD4
+/CD38+/HLA-DR+ in the group infected for more years (12 patients) at T1 is 48.79% less
than at T0, compared with a more marked reduction in the group recently infected (-56.86%).
Instead, the immune activation of CD8 T-cells (CD8+/CD38+/HLA-DR+) decreases only
in those subjects infected by less than 10 years (8 patients), showing a reduction of 61.68% at
T1 vs 36.60% in the other group.
We observed a positive correlation between the levels of D-dimer and years of infection
(CC: 0.583, p = 0.014). This finding persist also after the assumption of probiotics (CC: 0.592,
p = 0.006).
However, the sample is too small to appreciate significant correlations between the years of
infection and the degree of immune-activation.
Physical benefits perceived by patients. After probiotics assumption all the patients
enrolled reported beneficial effects consisting in substantial improvement in digestion, reduced
intestinal bloating, reduction of acute diarrhoeal episodes or constipation; a small fraction of
the subjects also stated reduction of allergic episodes and less fatigue. Only 29% of patients cer-
tifies that they have already taken in the past lactic acid bacteria and only a third of the sample
regularly assumes yogurt.
Fig 7. IL-6, nadir and immune activation at baseline. IL-6 levels at T0 were inversely correlated to CD4-Nadir (A) and CD4% (B), and positively correlated
with the frequencies of activated, CD4+CD38+ T-cells (C). P values <0.05 were considered statistically significant; r represents correlation coefficient.
doi:10.1371/journal.pone.0137200.g007
Probiotics and Inflammation in HIV Positive Patients
PLOS ONE | DOI:10.1371/journal.pone.0137200 September 16, 2015 11 / 15
The cost derived from the constant assumption of probiotics has been declared too expen-
sive by all participants.
Discussion
Chronic inflammation plays a central role in AIDS pathogenesis and contributes to morbidity
and mortality in HIV-infected adults [15]. In the current study, we observed that in cART
treated patients despite effective antiretroviral therapy the levels of the marker of immune acti-
vation were higher than healthy donors. All patients after 24 weeks probiotic supplementation
showed a weak increase of CD4 T cells in the blood and a significant reduction of the levels of
CD4+CD38+,CD4+HLA-DR+ and CD8+CD38+HLA-DR+ T cells. In addition also the
expression of activation markers on CD4 and CD8 surface at T1 was comparable to healthy
donors. The value of LBP was normalized after the assumption of probiotics and on the other
hand the levels of IL-6, CRP was similar to that observed in both group at both time of observa-
tion. These results underline and highlight that the use of probiotic can be useful to the recov-
ery of immunological responses in cART-treated individuals. To date is known the important
role of the inflammation to induce non-AIDS related events and to cause the aging of the
patients. The opportunity to integrate to cART probiotics intake to control the inflammation
status could contribute to take the life expectancy comparable to health donors[20–22].
However, the suggestions provided by this pilot study and other researches on the topic are
still preliminary and fragmentary to draw any firm conclusions. Instead they represent an
important incentive to justify larger studies to assess whether probiotic administration truly
could decrease inflammation and improve the prognosis of cART-treated, HIV-infected,
individuals.
In our study we observed a significant reduction of hsCRP after probiotics intake and this
marker is related to significant reduction of the cardiovascular diseases risk. In particular we
observed that the percentage of patients with elevated hsCRP decreased significantly from 45%
to 20% after the assumption of probiotics.
We did not find any significant correlation between both the nadir of CD4 T cells and the
time of exposure to the virus and the levels of immune activation. However we observed that
patients with CD4 T cells less than 250 cell/mL show a reduction of the levels of immune acti-
vation for CD38, HLA-DR and CD4 subpopulation. These data support that the value of CD4
less than 250 cell/μL is important to consider the risk of the progression of the infection. In fact
by guidelines the value of 250 cell/μl is important to begin the primary prophylaxis for infec-
tious disease such as pneumonia by Pneumocystis jirovecii.
The persistence of immune activation also after the recovery of the number of peripheral
CD4 T cells, together to the continuous undetectable levels of HIV-RNA and to the long expo-
sition to antiretroviral treatment suggests that could be useful combine the antiretroviral ther-
apy to the cure of GALT dysbiosis. Anyway at present, few studies report the use of prebiotics
or probiotics in HIV therapy. In available data, prebiotics were found to be effective in modu-
lating gut microbiota reconstruction and their use resulted in decreased LPS and sCD14 levels
and activation of CD4+ T-cell and NK cells. Prebiotics are used also to modulate resident gut
homeostasis [23, 24] and selectively promote growth of beneficial bacterial species. In this way,
pathogenic gut bacteria that maybe implicated in opportunistic infections, a hallmark of HIV
infection, are eliminated or reduced. Also probiotics have safely been administered to HIV-
infected individuals but their use resulted in modest improvements in CD4+ T cell counts and
clinical GI symptoms [25, 26]. Adequately administered probiotics can express antimicrobial
compounds that may kill or inhibit the growth of pathogenic microbial species in the gut, thus,
conferring a net health benefit [27, 28]. Moreover probiotics regulate the intestinal epithelial
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barrier, in fact increases in tight junction proteins as a response to the administration of probi-
otics have been demonstrated in vivo and in vitro [29]. The contribution of probiotics in HIV
disease management has been explored but conclusive knowledge is lacking.
The major limitation of this study is that this was not a randomized, controlled trial with a
comparable HIV-infected control group: in fact the lack of a proper comparison group, specifi-
cally HIV-positive subjects not taking probiotics, should be considered an important limitation
in the analysis of data.
Nevertheless we did measure parameters, longitudinally, in our treatment groups which
would, presumably and at least partially, control for many environmental factors. In fact cART
reduces T cell activation, but this parameter may remain abnormally elevated even after years of
HIV-RNA undetectability. Persistent immune activation despite sustained antiretroviral therapy
is associated with a blunted recovery of CD4+ T cells and augmented susceptibility to the devel-
opment of HIV infection-associated comorbidities [30–33]. Also, previous works studying tem-
poral reductions in immune activation after administration of cART showed how these levels
tend to plateau after several months of treatment. Therefore, we feel confident that our data mea-
sured a probiotic effect. Also, as mentioned above, the control group did not consume probiotics.
Considering the large number of potential confounders inherent in the study design, a
proper multivariate analysis should be more appropriate but was not possible to do for the
small sample size. Another potential caveat of this study is that the assessment of immune acti-
vation in peripheral blood was conducted only by determining the number of CD4+CD38+,
CD4+HLA-DR+ and CD8+CD38+HLA-DR+ T cells. Vice versa we do not think that the pre-
vious occasional probiotic consumption (as declared by patients in the questionnaire) influ-
enced the results obtained in the present study. Finally, we underline that the use of
questionnaire to assess the actual intake of probiotics is a simple way to know the adherence of
patients and could represent an important bias, but unfortunately we were not able to measure
directly the level of probiotics in the stools of patients.
In conclusion current and emerging studies support the concept that probiotic bacteria can
provide specific benefit in HIV infected patients during antiretroviral treatment by improve-
ment of the microbiota and reducing mucosal and systemic inflammation [25, 34].
However further longitudinal studies of the effects of the probiotics on the GALT will be
necessary to clarify the relationship between the persistence of immune activation in patients
with fully suppressed plasma viraemia.
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